Enrollment ChallengesEnrollment in the Ph1/1b study is currently on hold due to possible changes in the standard of care in an earlier line of therapy.
Financial PerformanceThe company's GAAP net loss was wider than expected, driven by higher-than-expected operating expenses.
Safety Concerns46.4% of patients treated with the combo experienced a G3+ TRAE, with G3 ALT/AST elevations occurring in 14% and 7% of patients, respectively; 7.1% of patients discontinued treatment due to a TRAE.